NFL Biosciences SA (EPA: ALNFL)

France flag France · Delayed Price · Currency is EUR
1.766
-0.084 (-4.54%)
Dec 20, 2024, 5:35 PM CET
18.52%
Market Cap 17.14M
Revenue n/a
Net Income n/a
Shares Out 9.71M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,739
Open 1.850
Previous Close 1.850
Day's Range 1.700 - 1.850
52-Week Range 1.330 - 3.280
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Country France
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

News

There is no news available yet.